Edward van der Horst - Dec 7, 2022 Form 3 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role
Chief Scientific Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
SNSE
Transactions as of
Dec 7, 2022
Transactions value $
$0
Form type
3
Date filed
12/16/2022, 03:30 PM
Next filing
Feb 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SNSE Common Stock 21.2K Dec 7, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SNSE Stock Option (Right to Buy) Dec 7, 2022 Common Stock 3.13K $16.32 Direct F2
holding SNSE Stock Option (Right to Buy) Dec 7, 2022 Common Stock 55.2K $3.22 Direct F3
holding SNSE Stock Option (Right to Buy) Dec 7, 2022 Common Stock 72.9K $19.00 Direct F4
holding SNSE Stock Option (Right to Buy) Dec 7, 2022 Common Stock 20K $8.69 Direct F5
holding SNSE Stock Option (Right to Buy) Dec 7, 2022 Common Stock 44K $4.30 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents: (1) 14,700 restricted stock units (the "RSUs"), with each RSU representing a contingent right to receive one share of the Issuer's common stock, vesting in four equal annual installments on each of February 15, 2023, February 15, 2024, February 15, 2025 and February 15, 2026, subject to the Reporting Person's continuous service with the Issuer through such vesting date; and (2) 6,473 shares purchased by the Reporting Person pursuant to the Issuer's 2021 Employee Stock Purchase Plan.
F2 25% of the shares subject to the option vest on the first anniversary of the vesting commencement date, September 3, 2021, and 1/48th of the shares subject to the option vest monthly thereafter over 36 months, subject to Reporting Person's continuous service as of each such date.
F3 25% of the shares subject to the option vest on the first anniversary of the vesting commencement date, February 15, 2022, and 1/48th of the shares subject to the option vest monthly thereafter over 36 months, subject to Reporting Person's continuous service as of each such date.
F4 25% of the shares subject to the option vest on the first anniversary of the vesting commencement date, February 4, 2023, and 1/48th of the shares subject to the option vest monthly thereafter over 36 months, subject to Reporting Person's continuous service as of each such date.
F5 25% of the shares subject to the option vest on the first anniversary of the vesting commencement date, October 8, 2023, and 1/48th of the shares subject to the option vest monthly thereafter over 36 months, subject to Reporting Person's continuous service as of each such date.
F6 25% of the shares subject to the option vest on the first anniversary of the vesting commencement date, February 15, 2024, and 1/48th of the shares subject to the option vest monthly thereafter over 36 months, subject to Reporting Person's continuous service as of each such date.

Remarks:

Exhibit 24 - Power of Attorney